Cell-Based In Vitro Assay Automation: Balancing Technology and Data Reproducibility/Predictability

G-protein-coupled receptors (GPCRs) are modulated by many marketed drugs, and as such, they continue to be key targets for drug discovery and development. Many GPCR targets at Merck Research Laboratories (MRL) are profiled using homogenous time-resolved fluorescence (HTRF) inositol monophosphate (IP-1) cell-based functional assays using adherent cells in 384-well microplates. Due to discrepancies observed across several in vitro assays supporting lead optimization structure–activity relationship (SAR) efforts, different assay paradigms were evaluated for removing growth medium from the assay plates prior to compound addition and determination of IP-1 accumulation. Remarkably, employing the noncontact centrifugation BlueWasher method leads to left-shifted potencies across multiple structural classes and rescues “false negatives” relative to the traditional manual evacuation method. Further, assay performance is improved, with the minimum significant ratio of challenging chemotypes dropping from ~5–6 to <3. While the impact of BlueWasher on a broad range of our GPCR targets remains to be determined, for highly protein-bound small molecules, it provides a path toward improving assay reproducibility across scientists and sites as well as reducing replicates in SAR assay support.

[1]  Viswanath Devanarayan,et al.  Minimum Significant Ratio of Selectivity Ratios (MSRSR) and Confidence in Ratio of Selectivity Ratios (CRSR) , 2012, Journal of biomolecular screening.

[2]  Sujata Sharma,et al.  Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40 , 2017, Nature Structural &Molecular Biology.

[3]  A Sewing,et al.  G-protein coupled receptor assays: to measure affinity or efficacy that is the question. , 2005, Combinatorial chemistry & high throughput screening.

[4]  J. Pin,et al.  D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. , 2006, Analytical biochemistry.

[5]  Jeffrey Strovel,et al.  Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies , 2016 .

[6]  Ling Huang,et al.  Use of the Site-Specific Retargeting Jump-In Platform Cell Line to Support Biologic Drug Discovery , 2015, Journal of biomolecular screening.

[7]  E. Trinquet,et al.  Monitoring Gq-coupled receptor response through inositol phosphate quantification with the IP-One assay , 2011, Expert opinion on drug discovery.

[8]  M. Prentki,et al.  Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. , 2000, Diabetes.

[9]  Kim E. Garbison,et al.  The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies , 2006, Journal of biomolecular screening.

[10]  S. Iturria,et al.  HTS Assay Validation , 2012 .

[11]  H. Hauser,et al.  Rapid Establishment of G-Protein-Coupled Receptor–Expressing Cell Lines by Site-Specific Integration , 2011, Journal of biomolecular screening.

[12]  S. Iturria,et al.  Assay Operations for SAR Support , 2012 .

[13]  C. Austin,et al.  Minimum Significant Ratio – A Statistic to Assess Assay Variability -- Assay Guidance Manual , 2013 .

[14]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[15]  Wen-long Huang,et al.  Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges , 2018, Medicinal research reviews.

[16]  J. Terwee,et al.  Increased consistency and efficiency in routine potency testing by bioassay with direct use of cryopreserved (ready-to-plate) cells. , 2011, Journal of immunological methods.

[17]  Kenneth Lundstrom,et al.  An Overview on GPCRs and Drug Discovery: Structure-Based Drug Design and Structural Biology on GPCRs , 2009, Methods in molecular biology.

[18]  E. Trinquet,et al.  HTRF: A Technology Tailored for Drug Discovery –A Review of Theoretical Aspects and Recent Applications , 2009, Current chemical genomics.

[19]  L. Ketscher,et al.  A one-day, dispense-only IP-One HTRF assay for high-throughput screening of Galphaq protein-coupled receptors: towards cells as reagents. , 2008, Assay and drug development technologies.

[20]  Christopher G Newton,et al.  Outsourcing lead optimisation--the quiet revolution. , 2004, Drug discovery today.

[21]  Sam Michael,et al.  Basics of Assay Equipment and Instrumentation for High Throughput Screening , 2016 .

[22]  K. Knagge,et al.  GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production , 2017, PloS one.

[23]  I. Kariv,et al.  Improvement of "hit-to-lead" optimization by integration of in vitro HTS experimental models for early determination of pharmacokinetic properties. , 2002, Combinatorial chemistry & high throughput screening.

[24]  O. J. Trask,et al.  Assay Guidance Manual , 2004 .

[25]  Noel Southall,et al.  Comparison on Functional Assays for Gq-Coupled GPCRs by Measuring Inositol Monophospate-1 and Intracellular Calcium in 1536-Well Plate Format , 2008, Current chemical genomics.